• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What BioMarin Shares New VOXZOGO Data Means For Shareholders

    Simply Wall St·10/13/2026 01:47:30
    Listen to the news
    • BioMarin Pharmaceutical reported extensive new clinical data across VOXZOGO and its skeletal pipeline, regulatory progress on a hypochondroplasia sNDA, and long term outcomes for POMBILITI + OPFOLDA and nivudirsen, all from multiple recent scientific meetings.
    • The breadth of VOXZOGO and BMN 333 data, along with regulatory filings that could extend BioMarin’s rare disease reach into hypochondroplasia, highlights how much of the firm’s outlook depends on scaling its skeletal growth disorder franchise.
    • This overview examines how BioMarin Pharmaceutical’s investment narrative is influenced by VOXZOGO’s label expansion effort into hypochondroplasia and related pipeline data.

    Scan how BioMarin Pharmaceutical’s rare disease push compares with other potential outliers in this space by reviewing the hand picked 20 high quality undiscovered gems in the sector.

    BioMarin Pharmaceutical Investment Narrative Recap

    To own BioMarin Pharmaceutical, you need to believe this rare disease portfolio, especially VOXZOGO, can translate its broad clinical footprint into better profitability and more efficient use of capital. The ASBMR data drop reinforces that the skeletal franchise is a major operational focus, but it does not by itself change the near term picture.

    The key short term swing factor remains execution on VOXZOGO label expansion and integration of recent deals into cleaner margins. The biggest risk is that higher R&D and deal activity keep net margins thin while the stock still carries a rich P/E, leaving little room if earnings delivery or cost control fall short.

    The VOXZOGO hypochondroplasia data and sNDA are the most relevant pieces here. VOXZOGO is already approved across several regions for achondroplasia, and the new hypochondroplasia results, including growth velocity and imaging data, go straight to the question of how far BioMarin Pharmaceutical can extend its skeletal franchise.

    If FDA and EMA reviews progress as the company plans and the broader VOXZOGO dataset supports long term benefit, that could reinforce the main growth driver investors are watching. Any delay, labeling constraint or weaker than expected real world uptake would cut directly against the margin expansion and earnings improvement many holders are counting on.

    What The Consensus Numbers Assume For BioMarin Pharmaceutical

    Analysts are building a BioMarin Pharmaceutical story that leans heavily on both faster top line expansion and a sharp shift in profitability. Their models assume revenue growth of 14.0% a year over the next three years, alongside profit margins moving from 2.1% today to 24.6% by year three. In that setup, earnings are projected to reach US$1.2b by 2029, compared with US$73.0m today, even though individual forecasts range widely from US$523.3m to US$2.1b.

    Pulling those inputs together, the consensus view suggests BioMarin Pharmaceutical would be generating about US$5.1b in revenue and US$1.2b in earnings by 2029, on a P/E of 18.4x if the analyst framework plays out. The stock today trades on about 44.2x earnings versus an external fair P/E estimate of 27.6x, which implies that a lot of this future margin and earnings profile is already embedded in the price.

    BioMarin Pharmaceutical's narrative projects US$5.1b revenue and US$1.2b earnings by 2029. This assumes 14.0% yearly revenue growth and requires earnings to rise by about US$1.1b from US$73.0m today.

    Uncover why BioMarin Pharmaceutical's fair value indicates a 65% potential upside to its current price that could narrow quickly.

    NasdaqGS:BMRN 1-Year Stock Price Chart
    NasdaqGS:BMRN 1-Year Stock Price Chart

    Exploring Other Perspectives

    You might see the ASBMR data as a clear win for BioMarin Pharmaceutical, yet the most cautious analysts focus on competition risk instead. Their lowest case already penciled in 11.8% annual revenue growth and US$527.2m earnings by 2029. That is far below the US$1.2b consensus, so views may change as new results are digested.

    Explore 3 other BioMarin Pharmaceutical fair value estimates, including one that suggests it could be worth just $91.62!

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond BioMarin Pharmaceutical?

    Once you have a view on BioMarin Pharmaceutical, it can help to stress test that thesis against other opportunities using the Simply Wall St Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.